Default company panoramic image
79fa0db0 3b12 46e0 8944 7ecfe0f61675

Myocept, Inc.

We develop topical recombinant proteins for anti-wrinkle markets not served by Botox because of aversion to needles and toxicity concerns.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Francisco, CA, USA
  • Currency USD
  • Founded December 2008
  • Employees 3
  • Website

Company Summary

We are developing a new class of topical muscle relaxants for the rapidly growing $3 billion anti-wrinkle market. Our compounds are smaller and more stable than botulinum toxins, capable of transdermal delivery and producing transient muscle paralysis. Our first product is a topical formulation, which can be sold in the US without pre-market approval. We also plan to develop pharmaceutical compounds for chronic back pain and muscle spasms.


  • Default avatar
    Bruce Cohen
    President and CEO

    Bruce Cohen has spent more than 25 years in leadership positions in life science and high tech companies. He was the founding President and CEO of three biotechnology companies: VitaPath Genetics, Cellerant Therapeutics and Acacia Biosciences. He also serves as CFO for GeneSoft Pharmaceuticals. In addition he held senior positions in business development and marketing at SEQUUS and Baxter. He has an MBA from Harvard Business School.

  • Default avatar
    Todd A Lorenz
    Founder and Executive Chair

    Todd Lorenz has been working with biotech start-ups for almost 20 years on funding, diligence and the proactive coordination of their IP strategy with ongoing research, regulatory and transactional developments. He co-founded Myocept with Lars Peters in 2008 and continues to maintain his active legal practice at Arnold & Porter. He received his scientific training at RPI and Harvard Medical School and his legal training at Boston University.

  • Default avatar
    Lars Erik Peters
    Founder and CSO

    Lars Peters has worked in research and product development in the biotech industry for more than 20 years with a particular emphasis on protein engineering and recombinant protein expression. He previously served as a Director of R&D at Qiagen and VP of R&D at Eppendorf 5Prime Inc. in Colorado, Before that, he co-founded biotech start-up InVitek GmbH in Germany. Lars received his graduate degree from the Lomonossov Moscow State University.